SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These ...

At the well-controlled HbA1c of the participants, previous literature shows current diabetes treatments have similar HbA1c decreases, so the HbA1c mean difference of long half-life PDE5 inhibitors may ...

Microtubules are essential components of cells, contributing to the maintenance of cell shape, intracellular transport, cell division, signal transduction, and various other functions. To discover ...

Mutations in isocitrate dehydrogenase 1/2 (mIDH1/2) are clinically significant biomarkers for diagnosis, prognosis, and therapy in cancer. To advance the noninvasive molecular imaging of mIDH1, we aim ...

Learn about the use of PDE5 inhibitors for lower urinary tract symptoms caused by premature ejaculation and BPH.

Erectile Dysfunction and PDE-5 Inhibitors The incidence of erectile dysfunction (defined as the inability to develop and sustain an erection sufficient for satisfactory sexual intercourse in 50% ...

PDE3 inhibitors are already in clinical use for treating heart failure, thrombosis, asthma, and other conditions, but their potential in promoting bone outgrowth by enhancing CNP signaling ...